Eurofins Transplant Genomics, Inc. (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce the first national in-network contract for TruGraf, its proprietary gene expression test for subclinical acute rejection. Humana, a leading health care company that offers a wide range of insurance products and health and … [Read more...] about TruGraf contracted with Humana for in-network coverage of Medicare kidney transplant patients

Easy, reliable, high-quality, and cost-effective testing for SARS-CoV-2 (COVID-19), in compliance with local regulatory requirements, is crucial to enabling millions of passengers to complete their journeys in comfort and safety. Eurofins has rapidly developed a broad network of around 500 testing centers across Europe and intends to have established around 1,000 testing centers by early … [Read more...] about Eurofins opens Europe-wide COVID-19 testing center network to facilitate summer travel

Eurofins Scientific (“Eurofins”), a global scientific leader in bioanalytical testing, announces that its subsidiary Eurofins Clinical Testing US Holdings, Inc. has entered into an agreement to acquire DNA Diagnostics Center (“DDC”), a leader in consumer genetic testing. DDC anticipates delivering revenues of over US$55m in 2021. DDC is one of the most highly accredited genetic-testing … [Read more...] about Eurofins to acquire DNA Diagnostics Center to grow genetic testing capabilities and significantly expand further into consumer testing market

Eurofins Technologies announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617, B.1.427/B.1.429, B.1.351 or P.1. The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 … [Read more...] about Eurofins launches a new multiplex PCR assay for rapid detection of the B.1.617 SARS-CoV-2 variant

As the number of types of COVID-19 Variants of Concern and of Interest increases, fast high throughput NGS sequencing is key to identify new variants while mutation specific PCR testing enables immediate detection and contact tracing.  Eurofins continues to develop innovative COVID-19 testing solutions and has now reached two important milestones. Eurofins has sequenced more than 125,000 … [Read more...] about Eurofins expands its global sequencing and mutation-specific PCR capabilities to detect COVID-19 Variants of Concern and of Interest

Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing announces the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a market leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET*, and … [Read more...] about Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise

Launch of the GSD NovaPrime® SARS-CoV-2 Direct RT-PCR The GSD NovaPrime® SARS-CoV-2 Direct RT-PCR is intended for the qualitative detection of SARS-CoV-2 from human nasopharyngeal swabs, eluted directly into deionised water without an additional RNA extraction process (extraction-free). Increase of global SARS-CoV-2 testing worldwide has posed new challenges to laboratories in nearly all … [Read more...] about Eurofins Launches New ultra-fast Extraction-free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices